Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | EBMT 2020: cellular therapy day

Annalisa Ruggeri • 31 Aug 2020
EBMT 2020
CAR-T

Annalisa Ruggeri, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, discusses cellular therapy, specifically the engineering of T-cells and the use of mesenchymal stem cells (MSCs) for treating graft-versus-host disease (GvHD). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Annalisa Ruggeri

10:00
Graft failure after unmanipulated haplo-HSCT with PT-Cy in AML
Annalisa Ruggeri • 26 Aug 2020
3:39
HSCT with T-cell add-back of rivogenlecleucel in acute leukemia
Annalisa Ruggeri • 7 Dec 2019
2:00
Association of HLA matching with outcome of UD-HSCT: EBMT study
Annalisa Ruggeri • 7 Dec 2019
2:26
abTCD haploidentical HSCT in pediatric AL: long-term outcomes
Annalisa Ruggeri • 7 Dec 2019
The content of VJHemOnc is intended for healthcare professionals